<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209530</url>
  </required_header>
  <id_info>
    <org_study_id>EN3835-212</org_study_id>
    <nct_id>NCT04209530</nct_id>
  </id_info>
  <brief_title>Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women</brief_title>
  <official_title>A Phase 2a, Open Label Study to Assess the Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Females Using Photonumeric Scales, Magnetic Resonance Imaging and Histopathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open-label, Phase 2a study to assess the photonumeric scale,&#xD;
      morphological, and histopathological changes associated with Collagenase Clostridium&#xD;
      Histolyticum (CCH) in adult women with moderate or severe Edematous Fibrosclerotic&#xD;
      Panniculopathy (EFP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to COVID-19 impact&#xD;
  </why_stopped>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Actual">October 5, 2020</completion_date>
  <primary_completion_date type="Actual">July 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change From Baseline (Screening) in PR-PCSS</measure>
    <time_frame>Day 71</time_frame>
    <description>Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-point photonumeric scale rating cellulite severity from &quot;0&quot; (None) to &quot;4&quot; (Severe) from a patient's perspective</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline (Screening) in CR-PCSS</measure>
    <time_frame>Day 22, Day 43 and Day 71</time_frame>
    <description>Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a 5-point photonumeric scale rating cellulite severity from &quot;0&quot; (None) to &quot;4&quot; (Severe) from a clinician's perspective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline (Screening) in Hexsel Cellulite Severity Scale (CSS)</measure>
    <time_frame>Day 22, Day 43 and Day 71</time_frame>
    <description>Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite, each feature is evaluated on a 4-point scale from &quot;0&quot; (Low) to &quot;3&quot; (High)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Before and After CCH Treatment</measure>
    <time_frame>Day 71</time_frame>
    <description>Magnetic Resonance Imaging (MRI) of cellulite before and after CCH treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathology Before and After CCH Treatment</measure>
    <time_frame>Day 71</time_frame>
    <description>Histopathology of biopsies defined by the observation of the biopsied specimen by a trained Pathologist</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Cellulite</condition>
  <condition>Edematous Fibrosclerotic Panniculopathy (EFP)</condition>
  <arm_group>
    <arm_group_label>Buttock &amp; Posterolateral Thigh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EN3835</intervention_name>
    <description>Collagenase Clostridium Histolyticum (CCH)</description>
    <arm_group_label>Buttock &amp; Posterolateral Thigh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have both buttocks or both posterolateral thighs with:&#xD;
&#xD;
               1. A score of 3 or 4 (moderate or severe) as reported by the investigator using the&#xD;
                  Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS).&#xD;
&#xD;
               2. A Hexsel Cellulite Severity Scale (CSS) Subsection A &quot;Number of Evident&#xD;
                  Depressions&quot; score of &gt;0, and Subsection B &quot;Depth of Depressions&quot; score of 2&#xD;
                  )medium depth depression) or 3 (deep depressions)..&#xD;
&#xD;
          2. Have a minimum of 2 well defined and isolated cellulite dimples.&#xD;
&#xD;
          3. Be willing to apply sunscreen to the treatment area before each exposure to the sun&#xD;
             for the duration of the study (from the Screening Visit through the Day 251/Early&#xD;
             Termination Visit).&#xD;
&#xD;
          4. Be judged to be in good health.&#xD;
&#xD;
          5. Have a negative pregnancy test.&#xD;
&#xD;
          6. Be willing and able to cooperate with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is from a vulnerable population, as defined by the United States (US) Code of Federal&#xD;
             Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national&#xD;
             regulations, including but not limited to, employees (temporary, part-time, full time,&#xD;
             etc) or a family member of the research staff conducting the study, or of the sponsor,&#xD;
             or of the contract research organization, or of the Institutional Review Board&#xD;
             (IRB)/Independent Ethics Committee (IEC).&#xD;
&#xD;
          2. Has a history of sensitivity or allergy to collagenase or any other excipient of CCH.&#xD;
&#xD;
          3. Has systemic conditions (coagulation disorders, malignancy, keloidal scar, abnormal&#xD;
             wound healing) that restricts study participation.&#xD;
&#xD;
          4. Has local (in areas to be treated) conditions (thrombosis, vascular disorder, active&#xD;
             infection/inflammation, active cutaneous alteration, tattoo/mole) that restricts study&#xD;
             participation.&#xD;
&#xD;
          5. Has skin laxity or linear undulations on the treatment region (both buttocks or both&#xD;
             thighs) that can be effaced by lifting skin.&#xD;
&#xD;
          6. Requires anticoagulant or antiplatelet medication during the study.&#xD;
&#xD;
          7. Has used or intends to use any of the local&#xD;
             applications/therapies/injections/procedures that restricts study participation.&#xD;
&#xD;
          8. Has used any form of artificial tanning (sprays, lotions, tanning booth, etc) within&#xD;
             the 30 days prior to the first dose of study treatment or plans to use any form of&#xD;
             artificial tanning during the study (through the Day 251/Early Termination Visit).&#xD;
&#xD;
          9. Has a positive HIV test and/or a positive Hepatitis B surface antigen (HBsAg) or&#xD;
             Hepatitis B core antibody (HBcAb) test at screening.&#xD;
&#xD;
         10. Has had any surgery, invasive procedure (eg, liposuction), injectable treatment (eg,&#xD;
             KYBELLAÂ®) or any similar treatment.&#xD;
&#xD;
         11. Has a history of keloids, hypertrophied scars, and/or other complications following&#xD;
             biopsy.&#xD;
&#xD;
         12. Has any contraindications for MRI(implant containing metal, internal metallic object,&#xD;
             permanent cosmetics/make-up, claustrophobia, syncope, low blood pressure, epilepsy,&#xD;
             asthma, sickle cell disease) that restricts study participation.&#xD;
&#xD;
         13. Has received any collagenase treatments at any time prior to treatment in this study&#xD;
             and/or has received EN3835 or CCH in a previous investigational study for cellulite.&#xD;
&#xD;
         14. Has previously received treatment with CCH in this clinical study.&#xD;
&#xD;
         15. Has received treatment with an investigational product within 30 days (or 5&#xD;
             half-lives, whichever is longer) of the Screening Visit.&#xD;
&#xD;
         16. Is pregnant and/or is providing breast milk or plans to become pregnant and/or to&#xD;
             provide breast milk during the course of the study.&#xD;
&#xD;
         17. Has any other condition(s) that, in the investigator's opinion, might indicate the&#xD;
             subject to be unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Dayoub</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endo Clinical Trial Site #1</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <results_first_submitted>July 23, 2021</results_first_submitted>
  <results_first_submitted_qc>September 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 7, 2021</results_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04209530/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04209530/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buttock</title>
          <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
        </group>
        <group group_id="P2">
          <title>Posterolateral Thigh</title>
          <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Terminated due to the major disruption in study visits and protocol assessments due to COVID-19</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buttock</title>
          <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
        </group>
        <group group_id="B2">
          <title>Posterolateral Thigh</title>
          <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="5.46"/>
                    <measurement group_id="B2" value="38.3" spread="1.96"/>
                    <measurement group_id="B3" value="43.0" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin Category (Fitzpatrick Scale)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>I (Pale white)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>II (Fair)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III (Darker white)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IV (Light brown)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>V (Brown)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>VI (Dark brown or black)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.67" spread="12.836"/>
                    <measurement group_id="B2" value="78.32" spread="1.836"/>
                    <measurement group_id="B3" value="76.24" spread="9.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.83" spread="9.390"/>
                    <measurement group_id="B2" value="163.41" spread="2.933"/>
                    <measurement group_id="B3" value="163.65" spread="6.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.73" spread="1.744"/>
                    <measurement group_id="B2" value="29.50" spread="0.300"/>
                    <measurement group_id="B3" value="28.49" spread="1.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change From Baseline (Screening) in PR-PCSS</title>
        <description>Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-point photonumeric scale rating cellulite severity from &quot;0&quot; (None) to &quot;4&quot; (Severe) from a patient's perspective</description>
        <time_frame>Day 71</time_frame>
        <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Buttock</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
          <group group_id="O2">
            <title>Posterolateral Thigh</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline (Screening) in PR-PCSS</title>
          <description>Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-point photonumeric scale rating cellulite severity from &quot;0&quot; (None) to &quot;4&quot; (Severe) from a patient's perspective</description>
          <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline (Screening) in CR-PCSS</title>
        <description>Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a 5-point photonumeric scale rating cellulite severity from &quot;0&quot; (None) to &quot;4&quot; (Severe) from a clinician's perspective</description>
        <time_frame>Day 22, Day 43 and Day 71</time_frame>
        <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Buttock</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
          <group group_id="O2">
            <title>Posterolateral Thigh</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline (Screening) in CR-PCSS</title>
          <description>Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a 5-point photonumeric scale rating cellulite severity from &quot;0&quot; (None) to &quot;4&quot; (Severe) from a clinician's perspective</description>
          <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline (Screening) in Hexsel Cellulite Severity Scale (CSS)</title>
        <description>Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite, each feature is evaluated on a 4-point scale from &quot;0&quot; (Low) to &quot;3&quot; (High)</description>
        <time_frame>Day 22, Day 43 and Day 71</time_frame>
        <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Buttock</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
          <group group_id="O2">
            <title>Posterolateral Thigh</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline (Screening) in Hexsel Cellulite Severity Scale (CSS)</title>
          <description>Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite, each feature is evaluated on a 4-point scale from &quot;0&quot; (Low) to &quot;3&quot; (High)</description>
          <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Before and After CCH Treatment</title>
        <description>Magnetic Resonance Imaging (MRI) of cellulite before and after CCH treatment</description>
        <time_frame>Day 71</time_frame>
        <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Buttock</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
          <group group_id="O2">
            <title>Posterolateral Thigh</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Before and After CCH Treatment</title>
          <description>Magnetic Resonance Imaging (MRI) of cellulite before and after CCH treatment</description>
          <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histopathology Before and After CCH Treatment</title>
        <description>Histopathology of biopsies defined by the observation of the biopsied specimen by a trained Pathologist</description>
        <time_frame>Day 71</time_frame>
        <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Buttock</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
          <group group_id="O2">
            <title>Posterolateral Thigh</title>
            <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
          </group>
        </group_list>
        <measure>
          <title>Histopathology Before and After CCH Treatment</title>
          <description>Histopathology of biopsies defined by the observation of the biopsied specimen by a trained Pathologist</description>
          <population>Because of the disruption of study conduct due to COVID-19, the study was prematurely terminated. No subjects completed assessments required for the Day 71 Visit and beyond. Only safety analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All (Serious and Non-Serious AEs) from Day 1 to Day 265</time_frame>
      <desc>All serious and non-serious AEs, whether elicited or observed during study visit or spontaneously reported by the participant, including events that occurred from the time the participant signed the study specific consent form until completion of or discharge from the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Buttock</title>
          <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
        </group>
        <group group_id="E2">
          <title>Posterolateral Thigh</title>
          <description>EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)&#xD;
EN3835: Collagenase Clostridium Histolyticum (CCH)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA, Version 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Saji Vijayan, MBBS</name_or_title>
      <organization>Endo Pharmaceuticals</organization>
      <phone>800-462-3636</phone>
      <email>clinicaltrials@endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

